ORIC Pharmaceuticals reported encouraging Phase 1b results for rinzimetostat, its allosteric PRC2 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC). When combined with approved androgen receptor inhibitors, 55% of evaluable patients achieved a ≥50% decline in prostate-specific antigen (PSA50) and 20% achieved a ≥90% decline (PSA90). Additionally, 59% of patients demonstrated circulating tumor DNA (ctDNA) clearance, suggesting deep molecular responses. Safety data showed a favorable profile with predominantly low-grade adverse events, supporting further dose optimization in combination regimens scheduled for reporting in Q1 2026.

At the same conference, ORIC presented Phase 1b data for enozertinib, its selective third-generation EGFR inhibitor targeting exon 20 insertion mutations in non-small cell lung cancer. The compound achieved an overall response rate of 67% in first-line patients and demonstrated a 100% intracranial response rate in those with measurable central nervous system disease. These outcomes highlight enozertinib’s potency against both systemic and brain metastases and underpin plans to advance the program rapidly into registrational trials.

ORIC strengthened its balance sheet and executive bench during 2025. The company extended its cash runway into the second half of 2028 through a series of equity and strategic financing activities, ensuring funding for ongoing Phase 3 preparations. Leadership additions include a new Chief Medical Officer and Head of Global Regulatory Affairs, both experienced in oncology drug approvals. These hires position ORIC to initiate its first global Phase 3 registrational trial of rinzimetostat in mCRPC in the first half of 2026 and support future commercialization efforts.